Sector News

Boston Scientific to buy Endo’s urology portfolio for $1.65 billion

March 2, 2015
Life sciences
(Reuters) – Medical device maker Boston Scientific Corp (BSX.N) said it will buy Endo International Plc’s (ENDP.O) American Medical Systems’ men’s and prostate health business for up to $1.65 billion.
 
The purchase ends a nearly decade-long deal drought for Boston Scientific, which has not completed a large takeover since its 2006 acquisition of heart device maker Guidant Corp for $27 billion.
 
The deal value includes additional $50 million in milestone based on 2016 sales, Boston Scientific said on Monday.
 
AMS’ men’s and prostate health businesses, which generated 2014 sales of about $400 million, provides treatments for conditions such as erectile dysfunction, enlarged prostate and bladder leakage.
 
Reuters reported last week that Boston Scientific was close to buying Endo’s AMS medical device unit.
 
Monday’s deal, which is expected to close in the third quarter of 2015, does not include AMS’ women’s health business.
 
Endo said in a separate statement it is evaluating strategic alternatives for the business.
 
Boston Scientific said it will finance the deal through a combination of existing and newly committed credit facilities.
 
BofA Merrill Lynch is Endo’s financial adviser and Skadden Arps Slate Meagher & Flom LLP the legal adviser.
 
J.P. Morgan Securities is financial adviser to Boston Scientific.
 
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D’Souza)

comments closed

Related News

May 27, 2023

Positive opinion for Novo Nordisk’s Sogroya

Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.

May 27, 2023

Medtronic acquires insulin patch pump maker EOFlow for $738M amid new MiniMed rollout

Life sciences

Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.

May 27, 2023

Apnimed cracks sleep apnea puzzle, hits primary goal in phase 2 study

Life sciences

Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”

How can we help you?

We're easy to reach